212 related articles for article (PubMed ID: 7724490)
1. Surface denaturation at solid-void interface--a possible pathway by which opalescent particulates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures.
Hsu CC; Nguyen HM; Yeung DA; Brooks DA; Koe GS; Bewley TA; Pearlman R
Pharm Res; 1995 Jan; 12(1):69-77. PubMed ID: 7724490
[TBL] [Abstract][Full Text] [Related]
2. Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations.
Awotwe-Otoo D; Agarabi C; Read EK; Lute S; Brorson KA; Khan MA
Int J Pharm; 2015 Jul; 490(1-2):341-50. PubMed ID: 25835267
[TBL] [Abstract][Full Text] [Related]
3. Root cause evaluation of particulates in the lyophilized indomethacin sodium trihydrate plug for parenteral administration.
Siddiqui A; Rahman Z; Khan SR; Awotwe-Otoo D; Khan MA
Int J Pharm; 2014 Oct; 473(1-2):545-51. PubMed ID: 25089509
[TBL] [Abstract][Full Text] [Related]
4. Stability characterization and appearance of particulates in a lyophilized formulation of a model peptide hormone-human secretin.
Srinivasan C; Siddiqui A; Korang-Yeboah M; Khan MA
Int J Pharm; 2015 Mar; 481(1-2):104-13. PubMed ID: 25636302
[TBL] [Abstract][Full Text] [Related]
5. Influence of histidine on the stability and physical properties of a fully human antibody in aqueous and solid forms.
Chen B; Bautista R; Yu K; Zapata GA; Mulkerrin MG; Chamow SM
Pharm Res; 2003 Dec; 20(12):1952-60. PubMed ID: 14725359
[TBL] [Abstract][Full Text] [Related]
6. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability--A step closer from promising technology to application.
Kasper JC; Schaffert D; Ogris M; Wagner E; Friess W
J Control Release; 2011 May; 151(3):246-55. PubMed ID: 21223985
[TBL] [Abstract][Full Text] [Related]
7. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
[TBL] [Abstract][Full Text] [Related]
8. Protein quantity on the air-solid interface determines degradation rates of human growth hormone in lyophilized samples.
Xu Y; Grobelny P; Von Allmen A; Knudson K; Pikal M; Carpenter JF; Randolph TW
J Pharm Sci; 2014 May; 103(5):1356-66. PubMed ID: 24623139
[TBL] [Abstract][Full Text] [Related]
9. Effect of moisture on the stability of a lyophilized humanized monoclonal antibody formulation.
Breen ED; Curley JG; Overcashier DE; Hsu CC; Shire SJ
Pharm Res; 2001 Sep; 18(9):1345-53. PubMed ID: 11683251
[TBL] [Abstract][Full Text] [Related]
10. Effect of temperature ramp rate during the primary drying process on the properties of amorphous-based lyophilized cake, Part 2: Successful lyophilization by adopting a fast ramp rate during primary drying in protein formulations.
Ohori R; Akita T; Yamashita C
Eur J Pharm Biopharm; 2018 Sep; 130():83-95. PubMed ID: 29913271
[TBL] [Abstract][Full Text] [Related]
11. Systematic investigation of the effect of lyophilizate collapse on pharmaceutically relevant proteins, part 2: stability during storage at elevated temperatures.
Schersch K; Betz O; Garidel P; Muehlau S; Bassarab S; Winter G
J Pharm Sci; 2012 Jul; 101(7):2288-306. PubMed ID: 22517663
[TBL] [Abstract][Full Text] [Related]
12. Thiol-disulfide exchange in peptides derived from human growth hormone during lyophilization and storage in the solid state.
Chandrasekhar S; Topp EM
J Pharm Sci; 2015 Apr; 104(4):1291-302. PubMed ID: 25631887
[TBL] [Abstract][Full Text] [Related]
13. An integrated process analytical technology (PAT) approach to monitoring the effect of supercooling on lyophilization product and process parameters of model monoclonal antibody formulations.
Awotwe Otoo D; Agarabi C; Khan MA
J Pharm Sci; 2014 Jul; 103(7):2042-2052. PubMed ID: 24840395
[TBL] [Abstract][Full Text] [Related]
14. Lyophilization cycle development for interleukin-2.
Vemuri S
Dev Biol Stand; 1992; 74():341-51. PubMed ID: 1592183
[TBL] [Abstract][Full Text] [Related]
15. Freeze-Drying of L-Arginine/Sucrose-Based Protein Formulations, Part 2: Optimization of Formulation Design and Freeze-Drying Process Conditions for an L-Arginine Chloride-Based Protein Formulation System.
Stärtzel P; Gieseler H; Gieseler M; Abdul-Fattah AM; Adler M; Mahler HC; Goldbach P
J Pharm Sci; 2015 Dec; 104(12):4241-4256. PubMed ID: 26422647
[TBL] [Abstract][Full Text] [Related]
16. Characterization of the physical stability of a lyophilized IgG1 mAb after accelerated shipping-like stress.
Telikepalli S; Kumru OS; Kim JH; Joshi SB; O'Berry KB; Blake-Haskins AW; Perkins MD; Middaugh CR; Volkin DB
J Pharm Sci; 2015 Feb; 104(2):495-507. PubMed ID: 25522000
[TBL] [Abstract][Full Text] [Related]
17. Effect of cyclophosphamide on the solid form of mannitol during lyophilization.
Patel K; Munjal B; Bansal AK
Eur J Pharm Sci; 2017 Apr; 101():251-257. PubMed ID: 28214546
[TBL] [Abstract][Full Text] [Related]
18. Instability of therapeutic proteins - An overview of stresses, stabilization mechanisms and analytical techniques involved in lyophilized proteins.
Butreddy A; Janga KY; Ajjarapu S; Sarabu S; Dudhipala N
Int J Biol Macromol; 2021 Jan; 167():309-325. PubMed ID: 33275971
[TBL] [Abstract][Full Text] [Related]
19. Effects of sugar additives on protein stability of recombinant human serum albumin during lyophilization and storage.
Han Y; Jin BS; Lee SB; Sohn Y; Joung JW; Lee JH
Arch Pharm Res; 2007 Sep; 30(9):1124-31. PubMed ID: 17958330
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of a recombinant ricin toxin A subunit vaccine through lyophilization.
Hassett KJ; Cousins MC; Rabia LA; Chadwick CM; O'Hara JM; Nandi P; Brey RN; Mantis NJ; Carpenter JF; Randolph TW
Eur J Pharm Biopharm; 2013 Oct; 85(2):279-86. PubMed ID: 23583494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
